Richard L Wasserman
Overview
Explore the profile of Richard L Wasserman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
1379
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel N, Walter J, Wasserman R, Rubinstein A, Kankirawatana S, Shepherd M, et al.
J Clin Immunol
. 2025 Mar;
45(1):81.
PMID: 40085358
Purpose: To investigate the efficacy, safety, tolerability, and serum IgG trough levels of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% in US pediatric patients with primary immunodeficiency diseases (PIDDs). Methods: This phase...
2.
Wasserman R
J Allergy Clin Immunol Glob
. 2025 Feb;
4(2):100393.
PMID: 39896210
No abstract available.
3.
Al-Shaikhly T, Cox A, Nowak-Wegrzyn A, Cianferoni A, Katelaris C, Ebo D, et al.
J Allergy Clin Immunol Pract
. 2024 Nov;
12(12):3242-3249.e1.
PMID: 39488768
Background: Pollen-food allergy syndrome (PFAS) is common among patients with allergic rhinitis. Treatment recommendations for patients with PFAS remain variable. Objective: To develop consensus recommendation statements for managing patients with...
4.
Wasserman R
J Food Allergy
. 2024 Sep;
6(1):15-20.
PMID: 39257600
A food reaction history is the basis of food allergy diagnoses. Several levels of food allergy diagnostic testing can confirm or refute the presence of food allergy. The choice of...
5.
Rubinstein A, Mabudian M, McNeil D, Patel N, Wasserman R, Gupta S, et al.
J Clin Immunol
. 2024 Aug;
44(8):181.
PMID: 39158670
Facilitated subcutaneous immunoglobulin (fSCIG) 10% is an immunoglobulin replacement therapy that utilizes recombinant human hyaluronidase (rHuPH20) to enhance immunoglobulin dispersion and absorption, allowing for longer treatment intervals similar to intravenous...
6.
Mack D, Wasserman R, Settipane R
J Food Allergy
. 2024 Jul;
4(2):17-18.
PMID: 39021853
No abstract available.
7.
Wasserman R
J Food Allergy
. 2024 Jul;
4(2):102-105.
PMID: 39021850
There is limited data addressing the optimal dose, dosing frequency, and duration of OIT maintenance. Using higher maintenance doses, more frequent dosing, and a long dosing duration makes it more...
8.
Mack D, Dribin T, Turner P, Wasserman R, Hanna M, Shaker M, et al.
J Allergy Clin Immunol
. 2024 Apr;
153(6):1621-1633.
PMID: 38597862
Background: Despite the promise of oral immunotherapy (OIT) to treat food allergies, this procedure is associated with potential risk. There is no current agreement about what elements should be included...
9.
Trevisonno J, Venter C, Pickett-Nairne K, Begin P, Cameron S, Chan E, et al.
J Allergy Clin Immunol Pract
. 2024 Mar;
12(7):1809-1818.e3.
PMID: 38492666
Background: Although oral immunotherapy (OIT) for food allergy is a reasonable treatment option, barriers to this procedure's implementation have not been extensively evaluated from a patient perspective. Objective: We evaluated...
10.
Wasserman R, Windom H, Jones D
J Allergy Clin Immunol Pract
. 2023 Dec;
11(12):3814-3815.
PMID: 38065643
No abstract available.